Tuberculosis is a chronic respiratory infection caused by Mycobacterium tuberculosis and is a major global public health concern in developing countries. 1,2 The discovery of anti-tuberculosis drugs had provided hope for tuberculosis eradication. Tragically, in the last 25 years, the misuse of these drugs has resulted in drug resistant tuberculosis. Drug resistance arises due to the improper use of antibiotics in chemotherapy of drug susceptible tuberculosis patients such as administration of improper treatment regimens by health care workers and failure to ensure that patients complete the whole course of the treatment. [3] [4] [5] Psychiatric issues present a challenge in the management of patients with multidrug resistant tuberculosis (MDR-TB). Psychiatric disorders can either be complications related to anti-tuberculosis drugs or induced by psychosocial factors. Both require aggressive JARCM/ Summer 2017; Vol. 5, No. 3 management. 6, 7 Psychiatric symptoms induced by anti-tuberculosis medications used in MDR-TB therapies are well known. Psychiatric morbidity in tuberculosis patients were recognized as the cause of poor compliance, and increased morbidity and mortality from the disease. Thus, treating psychiatric problems in patients with tuberculosis may substantially improve treatment adherence and prognosis. 1,2, 6, 8 The MDR-TB regiment is frequently reported to be associated with psychiatric disorders, particularly psychotic symptoms is cycloserine. Cycloserine is distributed throughout body fluids and tissues. There is no appreciable blood brain barrier to the drug, and cerebrospinal fluid (CSF) concentrations are approximately the same as those in plasma. 2 Symptoms usually appear within the first 2 weeks of therapy and disappear when the drug is withdrawn. The central manifestations include somnolence, headache, tremor, dysarthria, vertigo, confusion, nervousness, irritability, psychotic symptoms, suicide ideation, paranoid, catatonic and depressed reactions, twitching, ankle clonus, hyperreflexia, visual disturbances, paresis, and tonic-clonic or absence seizures. [8] [9] [10] [11] [12] The inward treatment facility for MDR-TB in Sardjito Hospital, Yogyakarta, Indonesia was established in 2014. This facility has provided us a unique opportunity to observe psychiatric disorders and symptoms in patients treated for MDR-TB that will most likely be misdiagnosed in the outpatient settings. In this study, we examined medical records of patients admitted to Sardjito Hospital for MDR-TB treatments and screened for psychiatric disorders.
This study was a descriptive analytic study. We examined all medical records of patients admitted to MDR-TB ward in Sardjito Hospital from January 2014 to July 2016. Only patients admitted for MDR-TB treatments were included in this study. We extracted data of demographic characteristics, MDR-TB treatments, and the diagnosis of psychiatric disorder and presence of psychotic symptoms. Psychiatric diagnosis was established by psychiatrist through direct clinical interview with patients as recorded in the medical records. The data was then tabulated and coded for statistical analyses. The statistical analyses were conducted using SPSS software (version X, IBM Corporation, Armonk, NY). The statistical significance was defined at P < 0.05.
In this study we identified 64 patients with MDR-TB admitted to Sardjito Hospital. The demographic and clinical characteristics of the subjects are presented in table 1. There were 21 patients (32.8%) who were diagnosed with psychiatric disorders, some of which had multiple psychiatric diagnoses (n = 9, 14.1%). The diagnoses were medication induced delirium (n = 1), substance/medication induced psychotic disorder (n = 6), substance/medication use depressive disorder (n = 2), depressive type schizoaffective disorder (n = 1), bipolar I disorder current episode severe manic with psychotic features (n = 1), mild depression (n = 1), moderate depression (n = 4), major depression without psychotic features (n = 1), major depression with psychotic features (n = 2), adjustment disorders with mixed anxiety and depressed mood (n = 1), adjustment disorder with anxiety (n = 7), acute stress disorder (n = 1), and insomnia (n = 4). History of previous psychiatric hospitalization (n = 1) and mild intellectual disability (n = 1) were also found among patients with psychiatric diagnoses.
The treatments for the psychiatric disorders varied. Three patients with adjustment disorder received only supportive psychotherapy and family psychoeducation.
The antipsychotics prescribed were haloperidol (1-10 mg/day) and risperidone (4 mg/day). Some patients experienced extrapyramidal symptoms and were prescribed trihexyphenidyl (4 mg/day). The antidepressants were amitriptyline (50 mg/day) and fluoxetine (10-20 mg/day). Mood stabilizers prescribed for patient with manic episode was valproic acid (500 mg/day). The anti-anxieties prescribed were alprazolam (0.5-1 mg/day), lorazepam (1 mg/day), and clobazam (10 mg/day).
Cycloserine dose was associated with the presence of psychiatric disorders in our subjects. Subjects with psychiatric disorders were prescribed with higher doses of cycloserine (P = 0.023). Age, weight, and height were not associated with psychiatric disorders in MDR-TB patients (table 2) .
We analyzed patient who had psychotic symptoms and found similar results. Patients who had psychotic symptoms were also prescribed with higher dose of cycloserine, although it was not statistically significant (P = 0.079). Age, weight, and height were not associated with psychotic symptoms in MDR-TB patients (Table 3) . We further analyzed the association between sex, marital status, level of education with psychiatric disorders in MDR-TB patients. Patients who completed junior high school or lower were considered to have low level of education and those completed senior high school or higher were considered to have high level of education. We found that sex was associated with psychiatric disorders. The proportion of psychiatric disorders was significantly higher in women compared to men (P = 0.023). Marital status and level of education were not associated to psychiatric disorders (Table 4) .
We further analyzed the association between sex, marital status, level of education, and psychotic symptoms in MDR-TB patients. We found that sex and level of education were significantly associated with psychotic symptoms. The proportion of psychotic symptoms were higher in women (P = 0.049) and in patients with low education (P = 0.033) ( Table 5 ).
The present study found that 32.8% MDR-TB patients admitted to Sardjito Hospital were diagnosed with psychiatric disorders and 52.4% of them had psychotic symptoms. Depression was the most common diagnosis. Psychiatric disorders and psychotics symptoms in MDR-TB patients are often associated with cycloserine administration. We found that significantly higher doses of cycloserine was administered in patients with psychiatric disorders but not in patients with psychotic symptoms. Psychiatric disorders and psychotic symptoms were more prevalent in women compared to men. Psychotic symptoms were also more prevalent in subjects with lower level of education. Tuberculosis has been associated with psychiatric disorders, particularly depression, and this has been recognized as a cause of poor compliance and a cause of increased morbidity and mortality from the disease. The psychiatric morbidity reported in Sardjito Hospital was lower than previous report in India (69.28%). 1 Treating psychiatric disorders in patients with tuberculosis may substantially improve treatment adherence and the disease prognosis.
Similar to our finding, depression was also prevalent among MDR-TB patients in India. 1 Prolonged treatment and duration of the disease could cause helplessness in these patients. This problem is worsened by social stigma toward tuberculosis. These lead to the development of depression. The treatment for depression will improve the patient outcome. Antidepressant treatments can be maintained during MDR-TB treatment course. 13 Psychiatric disorders are known adverse drug reactions of cycloserine. The possible neurobiological mechanisms may be binding to and modulation of N-methyl-D-aspartate receptor (NMDAR) antagonists and partial agonists at the NMDAR-associated glycine site, 5, 14 as well as gamma-Aminobutyric acid (GABA) elevation due to inhibition of GABA transferase. 15 We found that higher cycloserine dose was associated with the presence of psychiatric disorders. It is recommended to reduce the dosage of cycloserine in order to observe less severe manifestations of cycloserine toxicity. Antipsychotics are very useful for managing neuropsychiatric effects and can be continued throughout the duration of MDR-TB treatments. 12 Not only treatment regiments, but social factors, such as poverty, inadequate housing, and stigma are also significant determinants of psychiatric disorders in MDR-TB patients. 16 Stigma is one of the major concerns for MDR-TB patients. The impacts of stigma include social seclusion or rejection from family members, friends, neighbors, and/or health providers, internalized shame, financial instability, discrimination and its repercussion. 13 Lower level of education is associated with poor and ineffective coping styles. This results in higher prevalence of psychiatric problems. 1 In this study, lower level of education was associated with higher risk for psychotic symptoms but not for the psychiatric disorders. Lower education was also associated with mal-compliance to treatment regiments and subsequent prolonged treatments.
In conclusion, psychiatric disorders are relatively common in patients who are being treated for MDR-TB. Cycloserine can directly affect central nervous system and induce psychiatric symptoms. Cautious observation for psychiatric symptoms should be regularly conducted for patients receiving cycloserine. It is very prudent for psychiatrists to be aware of psychiatric manifestations of second-line anti-tubercular drugs to improve patient compliance and outcomes through early diagnosis and treatment. We also recommend aggressive and prolonged treatment due to the frequency and occasional severity of the psychiatric effects of MDR-TB drugs.
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